Neoplasm Metastasis Clinical Trials

13 recruiting

Neoplasm Metastasis Trials at a Glance

14 actively recruiting trials for neoplasm metastasis are listed on ClinicalTrialsFinder across 6 cities in 30 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in Detroit, Houston, and Barcelona. Lead sponsors running neoplasm metastasis studies include Eli Lilly and Company, Eiji Shinozaki, and Centre Hospitalier Universitaire de la Guadeloupe.

Browse neoplasm metastasis trials by phase

Treatments under study

About Neoplasm Metastasis Clinical Trials

Looking for clinical trials for Neoplasm Metastasis? There are currently 13 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neoplasm Metastasis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neoplasm Metastasis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 3

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company920 enrolled317 locationsNCT07174336
Recruiting
Phase 2

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Neoplasm MetastasisEndometrial NeoplasmsNeoplasm Recurrence, Local
Shandong Cancer Hospital and Institute30 enrolled1 locationNCT06532539
Recruiting
Phase 1

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms
Eli Lilly and Company535 enrolled84 locationsNCT05614739
Recruiting
Phase 3

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,080 enrolled260 locationsNCT07213804
Recruiting
Phase 1

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Breast NeoplasmsColorectal NeoplasmsProstate Neoplasm+2 more
Eli Lilly and Company421 enrolled28 locationsNCT07114601
Recruiting
Phase 3

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Urinary Bladder NeoplasmsNeoplasm MetastasisCarcinoma, Transitional Cell
Eli Lilly and Company450 enrolled281 locationsNCT07218380
Recruiting

PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

Breast CancerBreast NeoplasmsNeoplasm Metastasis
AstraZeneca800 enrolled107 locationsNCT05573893
Recruiting
Phase 1

Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

Head and Neck NeoplasmsNeoplasm MetastasisCarcinoma, Squamous Cell+3 more
University of Chicago36 enrolled1 locationNCT06912087
Recruiting
Not Applicable

Clinical, Genetic and Environmental Determinants of Prostate Cancer Progression.

Neoplasm MetastasisAdenocarcinomaProstatic Neoplasm+1 more
Centre Hospitalier Universitaire de la Guadeloupe3,000 enrolled2 locationsNCT06046131
Recruiting

Bone Metastases Database of Patients Treated Surgically for Impending or Pathologic Fracture of Long Bones

Neoplasm Metastasis
Istituto Ortopedico Rizzoli120 enrolled1 locationNCT03416959
Recruiting
Phase 1

Study of a Tankyrase Inhibitor RK-582 for Patients With Unresectable Metastatic Colorectal Cancer

Unresectable Colorectal Neoplasm Metastasis
Eiji Shinozaki48 enrolled1 locationNCT06853496
Recruiting
Not Applicable

Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases

Neoplasm MetastasisSpinal Cord Diseases
Henry Ford Health System60 enrolled1 locationNCT05023772
Recruiting
Phase 2

Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer

Neoplasm MetastasisPancreatic NeoplasmsHepatic Metastasis of Pancreatic Cancer
Ruijin Hospital40 enrolled1 locationNCT06538623
Recruiting
Phase 1Phase 2

EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers

NeoplasmsNeoplasm MetastasisMetastatic Gastrointestinal Carcinoid Tumor
Shanghai EpimAb Biotherapeutics Co., Ltd.152 enrolled14 locationsNCT05176665